Evidence map›Paper›PMID 31044149›Full record

ArticleNeurology(R) neuroimmunology & neuroinflammation2019

Human C5-specific single-chain variable fragment ameliorates brain injury in a model of NMOSD.

Wenli Zhu, Zhen Wang, Suying Hu, Ye Gong, Yuanchu Liu, Huanhuan Song, Xiaoli Ding, Ying Fu, Yaping Yan

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology(R) neuroimmunology & neuroinflammation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Wenli ZhuKey Laboratory of the Ministry of Education for Medicinal Resources and Natural Pharmaceutical Chemistry (W.Z., Z.W., S.H., Y.G., Y.L., H.S., X.D., Y.F., Y.Y.), National Engineering Laboratory for Resource Development of Endangered Crude Drugs in Northwest of China, College of Life Sciences, Shaanxi Normal University, Xi'an; Department of Neurology (W.Z.), Tianjin Neurological Institute, Tianjin Medical University General Hospital; and Department of Neurology (Z.W.), Xuanwu Hospital, Capital Medical University, Beijing, China.
Zhen WangKey Laboratory of the Ministry of Education for Medicinal Resources and Natural Pharmaceutical Chemistry (W.Z., Z.W., S.H., Y.G., Y.L., H.S., X.D., Y.F., Y.Y.), National Engineering Laboratory for Resource Development of Endangered Crude Drugs in Northwest of China, College of Life Sciences, Shaanxi Normal University, Xi'an; Department of Neurology (W.Z.), Tianjin Neurological Institute, Tianjin Medical University General Hospital; and Department of Neurology (Z.W.), Xuanwu Hospital, Capital Medical University, Beijing, China.
Suying HuKey Laboratory of the Ministry of Education for Medicinal Resources and Natural Pharmaceutical Chemistry (W.Z., Z.W., S.H., Y.G., Y.L., H.S., X.D., Y.F., Y.Y.), National Engineering Laboratory for Resource Development of Endangered Crude Drugs in Northwest of China, College of Life Sciences, Shaanxi Normal University, Xi'an; Department of Neurology (W.Z.), Tianjin Neurological Institute, Tianjin Medical University General Hospital; and Department of Neurology (Z.W.), Xuanwu Hospital, Capital Medical University, Beijing, China.
Ye GongKey Laboratory of the Ministry of Education for Medicinal Resources and Natural Pharmaceutical Chemistry (W.Z., Z.W., S.H., Y.G., Y.L., H.S., X.D., Y.F., Y.Y.), National Engineering Laboratory for Resource Development of Endangered Crude Drugs in Northwest of China, College of Life Sciences, Shaanxi Normal University, Xi'an; Department of Neurology (W.Z.), Tianjin Neurological Institute, Tianjin Medical University General Hospital; and Department of Neurology (Z.W.), Xuanwu Hospital, Capital Medical University, Beijing, China.
Yuanchu LiuKey Laboratory of the Ministry of Education for Medicinal Resources and Natural Pharmaceutical Chemistry (W.Z., Z.W., S.H., Y.G., Y.L., H.S., X.D., Y.F., Y.Y.), National Engineering Laboratory for Resource Development of Endangered Crude Drugs in Northwest of China, College of Life Sciences, Shaanxi Normal University, Xi'an; Department of Neurology (W.Z.), Tianjin Neurological Institute, Tianjin Medical University General Hospital; and Department of Neurology (Z.W.), Xuanwu Hospital, Capital Medical University, Beijing, China.
Huanhuan SongKey Laboratory of the Ministry of Education for Medicinal Resources and Natural Pharmaceutical Chemistry (W.Z., Z.W., S.H., Y.G., Y.L., H.S., X.D., Y.F., Y.Y.), National Engineering Laboratory for Resource Development of Endangered Crude Drugs in Northwest of China, College of Life Sciences, Shaanxi Normal University, Xi'an; Department of Neurology (W.Z.), Tianjin Neurological Institute, Tianjin Medical University General Hospital; and Department of Neurology (Z.W.), Xuanwu Hospital, Capital Medical University, Beijing, China.
Xiaoli DingKey Laboratory of the Ministry of Education for Medicinal Resources and Natural Pharmaceutical Chemistry (W.Z., Z.W., S.H., Y.G., Y.L., H.S., X.D., Y.F., Y.Y.), National Engineering Laboratory for Resource Development of Endangered Crude Drugs in Northwest of China, College of Life Sciences, Shaanxi Normal University, Xi'an; Department of Neurology (W.Z.), Tianjin Neurological Institute, Tianjin Medical University General Hospital; and Department of Neurology (Z.W.), Xuanwu Hospital, Capital Medical University, Beijing, China.
Ying FuKey Laboratory of the Ministry of Education for Medicinal Resources and Natural Pharmaceutical Chemistry (W.Z., Z.W., S.H., Y.G., Y.L., H.S., X.D., Y.F., Y.Y.), National Engineering Laboratory for Resource Development of Endangered Crude Drugs in Northwest of China, College of Life Sciences, Shaanxi Normal University, Xi'an; Department of Neurology (W.Z.), Tianjin Neurological Institute, Tianjin Medical University General Hospital; and Department of Neurology (Z.W.), Xuanwu Hospital, Capital Medical University, Beijing, China.
Yaping YanKey Laboratory of the Ministry of Education for Medicinal Resources and Natural Pharmaceutical Chemistry (W.Z., Z.W., S.H., Y.G., Y.L., H.S., X.D., Y.F., Y.Y.), National Engineering Laboratory for Resource Development of Endangered Crude Drugs in Northwest of China, College of Life Sciences, Shaanxi Normal University, Xi'an; Department of Neurology (W.Z.), Tianjin Neurological Institute, Tianjin Medical University General Hospital; and Department of Neurology (Z.W.), Xuanwu Hospital, Capital Medical University, Beijing, China.
Shaanxi Normal University · CNCapital Medical University · CNTianjin Medical University General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Using phage display, we sought to screen single-chain variable fragments (scFvs) against complement C5 to treat neuromyelitis optica spectrum disorder (NMOSD). Methods: After 5 rounds of phage display, we isolated individual clones and identified phage clones specifically binding to C5 using ELISA. Using aquaporin-4 (AQP4)-transfected cells in vitro, we confirmed whether these scFvs prevented complement-dependent cytotoxicity (CDC) caused by the serum of patients with NMOSD and human complement (hC). We selected an NMOSD mouse model, in which intracerebral NMOSD immunoglobulin G (IgG) and hC injections induce NMOSD-like lesions in vivo. Results: We obtained scFvs to test specificity and blocking efficiency. The scFv C5B3 neutralized C5 in the complement activation pathway, which prevented AQP4-IgG-mediated CDC in AQP4-transfected cells. In an NMOSD mouse model, C5B3 prevented AQP4 and astrocyte loss, decreased demyelination, and reduced inflammatory infiltration and membrane attack complex formation in lesions. Conclusions: We used phage display to screen C5B3 against C5, which was effective in inhibiting cytotoxicity in vitro and preventing CNS pathology in vivo.

Indexed as

Aquaporin 4Complement ActivationComplement C5Single-Chain AntibodiesAnimalsBrain InjuriesCell Surface Display TechniquesDisease Models, AnimalFemaleHumansMiceMice, Inbred C57BLNeuromyelitis OpticaAquaporin 4Complement C5Single-Chain Antibodies

Identifiers

PMID31044149
PMCPMC6467685
OpenAlexW2930560260

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.